{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,4]],"date-time":"2026-06-04T10:58:10Z","timestamp":1780570690203,"version":"3.54.1"},"reference-count":43,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2021,8,1]],"date-time":"2021-08-01T00:00:00Z","timestamp":1627776000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,8,1]],"date-time":"2021-08-01T00:00:00Z","timestamp":1627776000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2021,5,18]],"date-time":"2021-05-18T00:00:00Z","timestamp":1621296000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100010882","name":"Tianjin Municipal Education Commission","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100010882","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Annals of Diagnostic Pathology"],"published-print":{"date-parts":[[2021,8]]},"DOI":"10.1016\/j.anndiagpath.2021.151755","type":"journal-article","created":{"date-parts":[[2021,5,10]],"date-time":"2021-05-10T23:08:22Z","timestamp":1620688102000},"page":"151755","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":5,"special_numbering":"C","title":["The role of different PI3K protein subtypes in the metastasis, angiogenesis and clinical prognosis of hepatocellular carcinoma"],"prefix":"10.1016","volume":"53","author":[{"given":"Na","family":"Che","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiulan","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nan","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yanhui","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chunsheng","family":"Ni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Danfang","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shuai","family":"Su","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaohui","family":"Liang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fan","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yue","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.anndiagpath.2021.151755_bb0005","doi-asserted-by":"crossref","unstructured":"Michael C Wallace, David Preen, Gary P Jeffrey, et al. The evolving epidemiology of hepatocellular carcinoma: a global perspective. Expert Rev Gastroenterol Hepatol 2015; Jun;9(6):765\u2013779. doi:https:\/\/doi.org\/10.1586\/17474124.2015.1028363.","DOI":"10.1586\/17474124.2015.1028363"},{"issue":"1","key":"10.1016\/j.anndiagpath.2021.151755_bb0010","first-page":"151","article-title":"Bladder cancer cell-secreted exosomal miR-21 activates the PI3K\/AKT pathway in macrophages to promote cancer progression","volume":"56","author":"Lin","year":"2020","journal-title":"Int J Oncol"},{"key":"10.1016\/j.anndiagpath.2021.151755_bb0015","doi-asserted-by":"crossref","unstructured":"Jayashree Karar, Amit Maity. PI3K\/AKT\/mTOR pathway in angiogenesis. Front Mol Neurosci 2011; Dec 2; 4:51. doi:https:\/\/doi.org\/10.3389\/fnmol.2011.00051.","DOI":"10.3389\/fnmol.2011.00051"},{"key":"10.1016\/j.anndiagpath.2021.151755_bb0020","doi-asserted-by":"crossref","unstructured":"Bing-Hua Jiang, Ling-Zhi Liu. PI3K\/PTEN signaling in angiogenesis and tumorigenesis. Adv Cancer Res 2009; 102:19\u201365. doi:https:\/\/doi.org\/10.1016\/s0065-230x(09)02002-8.","DOI":"10.1016\/S0065-230X(09)02002-8"},{"key":"10.1016\/j.anndiagpath.2021.151755_bb0025","doi-asserted-by":"crossref","unstructured":"Shweta Joshi, Alok R Singh, Muamera Zulcic. A macrophage-dominant PI3K isoform controls hypoxia-induced HIF1\u03b1 and HIF2\u03b1 stability and tumor growth, angiogenesis, and metastasis. Mol Cancer Res 2014; Oct;12(10):1520\u201331. doi:https:\/\/doi.org\/10.1158\/1541-7786.mcr-13-0682.","DOI":"10.1158\/1541-7786.MCR-13-0682"},{"key":"10.1016\/j.anndiagpath.2021.151755_bb0030","doi-asserted-by":"crossref","unstructured":"Akintunde Akinleye, Parthu Avvaru, Muhammad Furqan, et al. Phosphatidylinositol 3-kinase (PI3K) inhibitors as cancer therapeutics. J Hematol Oncol 2013; Nov 22, 6(1):88.doi:https:\/\/doi.org\/10.1186\/1756-8722-6-88.","DOI":"10.1186\/1756-8722-6-88"},{"key":"10.1016\/j.anndiagpath.2021.151755_bb0035","doi-asserted-by":"crossref","unstructured":"B. Verret, J. Cortes, T Bachelot, et al. Efficacy of PI3K inhibitors in advanced breast cancer. Ann Oncol 2019; Dec 1;30 (Supplement 10): x12\u2013x20. doi:https:\/\/doi.org\/10.1093\/annonc\/mdz381.","DOI":"10.1093\/annonc\/mdz381"},{"key":"10.1016\/j.anndiagpath.2021.151755_bb0040","doi-asserted-by":"crossref","unstructured":"Jing Yang, Ji Nie, Xuelei Ma,et al. Targeting PI3K in cancer: mechanisms and advances in clinical trials. Mol Cancer 2019; Feb 19; 18(1):26.doi:https:\/\/doi.org\/10.1186\/s12943-019-0954-x.","DOI":"10.1186\/s12943-019-0954-x"},{"key":"10.1016\/j.anndiagpath.2021.151755_bb0045","doi-asserted-by":"crossref","unstructured":"Massacesi C, Di Tomaso E, Urban P, et al. PI3K inhibitors as new cancer therapeutics: implications for clinical trial design. OncoTargets Ther 2016;9:203\u2013210.doi:https:\/\/doi.org\/10.2147\/ott.s89967.","DOI":"10.2147\/OTT.S89967"},{"issue":"6","key":"10.1016\/j.anndiagpath.2021.151755_bb0050","doi-asserted-by":"crossref","first-page":"620","DOI":"10.7150\/ijms.8251","article-title":"PIK3CA gene amplification and PI3K p110\u03b1 protein expression in breast carcinoma","volume":"11","author":"Firoozinia","year":"2014","journal-title":"Int J Med Sci"},{"key":"10.1016\/j.anndiagpath.2021.151755_bb0055","doi-asserted-by":"crossref","unstructured":"Jeremy Johnson, Zeta Chow, Dana Napier, et al. Targeting PI3K and AMPK\u03b1 Signaling alone or in combination to enhance radiosensitivity of triple negative breast cancer. Cells 2020;May 19;9(5):1253.doi:https:\/\/doi.org\/10.3390\/cells9051253.","DOI":"10.3390\/cells9051253"},{"key":"10.1016\/j.anndiagpath.2021.151755_bb0060","doi-asserted-by":"crossref","unstructured":"Wai Kien Yip, Pei Yuan He, Maizaton Atmadini Abdullah. Increased expression of phosphatidylinositol 3-kinase p110\u03b1 and gene amplification of PIK3CA in nasopharyngeal carcinoma. Pathol Oncol Res 2016; Apr;22(2):413\u20139. doi:https:\/\/doi.org\/10.1007\/s12253-015-0007-8.","DOI":"10.1007\/s12253-015-0007-8"},{"key":"10.1016\/j.anndiagpath.2021.151755_bb0065","unstructured":"Xiong Yan, Qu Linlin, Li Dong, et al. Clinical significance and mechanism of upregulation of PI3K p110\u03b1 in non-small cell lung carcinoma. Chin J Oncol 2017;39(10):737\u2013743. doi:https:\/\/doi.org\/10.3760\/cma.j.issn.0253-3766.2017.10.004."},{"key":"10.1016\/j.anndiagpath.2021.151755_bb0070","doi-asserted-by":"crossref","unstructured":"Svenja No\u00c8lting, Jakob Rentsch, Helma Freitag, et al. The selective PI3K\u03b1 inhibitor BYL719 as a novel therapeutic option for neuroendocrine tumors: results from multiple cell line models[J] PLoS One, 2017, August 11,12(8):0182852. doi:https:\/\/doi.org\/10.1371\/journal.pone.0182852.","DOI":"10.1371\/journal.pone.0182852"},{"key":"10.1016\/j.anndiagpath.2021.151755_bb0075","doi-asserted-by":"crossref","unstructured":"Shidong Jia, Zhenning Liu, Sen Zhang, et al. Essential roles of PI(3)K-p110beta in cell growth, metabolism and tumorigenesis. Nature 2008; August 7; 454(7205): 776\u2013779.doi:https:\/\/doi.org\/10.1038\/nature07091.","DOI":"10.1038\/nature07091"},{"key":"10.1016\/j.anndiagpath.2021.151755_bb0080","doi-asserted-by":"crossref","unstructured":"Kevin J Pridham, Lamvy Le, Sujuan Guo.PIK3CB\/p110\u03b2 is a selective survival factor for glioblastoma. Neuro-Oncology 2018; Mar 27;20(4):494\u2013505.doi:https:\/\/doi.org\/10.1093\/neuonc\/nox181.","DOI":"10.1093\/neuonc\/nox181"},{"key":"10.1016\/j.anndiagpath.2021.151755_bb0085","doi-asserted-by":"crossref","unstructured":"Thomas Karlsson,Camilla Krakstad, Ingvild L\u00f8berg Tangen, et al. Endometrial cancer cells exhibit high expression of p110\u03b2 and its selective inhibition induces variable responses on PI3K signaling, cell survival and proliferation. Oncotarget 2017 Jan 17;8(3):3881\u20133894.doi:10.18632\/oncotarget.13989.","DOI":"10.18632\/oncotarget.13989"},{"key":"10.1016\/j.anndiagpath.2021.151755_bb0090","doi-asserted-by":"crossref","unstructured":"Evagelia Goulielmaki, Miriam Bermudez-Brito, Marqarita Andreou, et al. Pharmacological inactivation of the PI3Kp110\u03b4 prevents breast tumor progression by targeting cancer cells and macrophages. Cell Death Dis 2018; Jun7;9(6):678 doi:https:\/\/doi.org\/10.1038\/s41419-018-0717-4.","DOI":"10.1038\/s41419-018-0717-4"},{"key":"10.1016\/j.anndiagpath.2021.151755_bb0095","doi-asserted-by":"crossref","unstructured":"Tzenaki N, Papakonstanti EA. p110\u03b4 PI3 kinase pathway: emerging roles in cancer. Front Oncol 2013; Mar 1; 3:40. doi:https:\/\/doi.org\/10.3389\/fonc.2013.00040.","DOI":"10.3389\/fonc.2013.00040"},{"key":"10.1016\/j.anndiagpath.2021.151755_bb0100","doi-asserted-by":"crossref","unstructured":"Niki Tzenaki, Margarita Andreou, Kalliopi Stratigi, et al, High levels of p110\u03b4 PI3K expression in solid tumor cells suppress PTEN activity, generating cellular sensitivity to p110\u03b4 inhibitors through PTEN activation. FASEB J 2012; Jun;26(6):2498\u2013508. doi:https:\/\/doi.org\/10.1096\/fj.11-198192.","DOI":"10.1096\/fj.11-198192"},{"key":"10.1016\/j.anndiagpath.2021.151755_bb0105","doi-asserted-by":"crossref","unstructured":"Lydia Xenou, Evangelia A Papakonstanti. p110\u03b4 PI3K as a therapeutic target of solid tumors. Clin Sci (Lond) 2020; Jun 26;134(12):1377\u20131397. doi:https:\/\/doi.org\/10.1042\/cs20190772.","DOI":"10.1042\/CS20190772"},{"key":"10.1016\/j.anndiagpath.2021.151755_bb0110","doi-asserted-by":"crossref","unstructured":"Jing-Song Chen, Jiong-Qiang Huang, Bing Luo, et al. PIK3CD induces cell growth and invasion by activating AKT\/GSK-3\u03b2\/\u03b2-catenin signaling in colorectal cancer. Cancer Sci 2019 Mar;110(3):997\u20131011.doi:https:\/\/doi.org\/10.1111\/cas.13931.","DOI":"10.1111\/cas.13931"},{"key":"10.1016\/j.anndiagpath.2021.151755_bb0115","doi-asserted-by":"crossref","unstructured":"Xiulan Zhao,Taosun,Na Che.et al.Promotion of hepatocellular carcinoma metastasis through matrix metalloproteinase activation by epithelial-mesenchymal transition regulator Twist1. J Cell Mol Med 2011,15(3):691\u2013700. doi:https:\/\/doi.org\/10.1111\/j.1582-4934.2010.01052.x.","DOI":"10.1111\/j.1582-4934.2010.01052.x"},{"issue":"1","key":"10.1016\/j.anndiagpath.2021.151755_bb0120","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1186\/s12964-019-0423-6","article-title":"Downregulation of exosomal CLEC3B in hepatocellular carcinoma promotes metastasis and angiogenesis via AMPK and VEGF signals","volume":"17","author":"Dai","year":"2019","journal-title":"Cell Commun Signal"},{"key":"10.1016\/j.anndiagpath.2021.151755_bb0125","doi-asserted-by":"crossref","unstructured":"Jinduan Lin,Shunwang Cao,Yu Wang.et al.Long non-coding RNA UBE2CP3 enhances HCC cell secretion of VEGFA and promotes angiogenesis by activating ERK1\/2\/HIF-1\u03b1\/VEGFA signaling in hepatocellular carcinoma. J Exp Clin Cancer Res 2018 Jun4;37(1):113.doi:https:\/\/doi.org\/10.1186\/s13046-018-0727-1.","DOI":"10.1186\/s13046-018-0727-1"},{"key":"10.1016\/j.anndiagpath.2021.151755_bb0130","doi-asserted-by":"crossref","unstructured":"Gillian L Dornan, John E Burke. Molecular mechanisms of human disease mediated by oncogenic and primary immunodeficiency mutations in class IA phosphoinositide 3-kinases. Front Immunol 2018; Mar 19,9:575. doi:https:\/\/doi.org\/10.3389\/fimmu.2018.00575.","DOI":"10.3389\/fimmu.2018.00575"},{"key":"10.1016\/j.anndiagpath.2021.151755_bb0135","doi-asserted-by":"crossref","unstructured":"Klaus Okkenhaug, Mariona Graupera, Bart Vanhaesebroec, et al. Targeting PI3K in cancer: impact on tumor cells, their protective stroma, angiogenesis and immunotherapy. Cancer Discov 2016;6(10):1090\u20131105. doi:https:\/\/doi.org\/10.1158\/2159-8290.cd-16-0716.","DOI":"10.1158\/2159-8290.CD-16-0716"},{"key":"10.1016\/j.anndiagpath.2021.151755_bb0140","doi-asserted-by":"crossref","unstructured":"Jayashree Karar, Amit Maity. PI3K\/AKT\/mTOR Pathway in Angiogenesis. Front Mol Neurosci 2011; Dec2, 4: 51.doi:https:\/\/doi.org\/10.3389\/fnmol.2011.00051.","DOI":"10.3389\/fnmol.2011.00051"},{"key":"10.1016\/j.anndiagpath.2021.151755_bb0145","doi-asserted-by":"crossref","unstructured":"Yuichi Hisamatsu, Eiji Oki, Hajime Otsu,et al. Effect of EGFR and p-AKT overexpression on chromosomal instability in gastric cancer. Ann Surg Oncol 2016; Jun;23(6):1986\u201392. doi:https:\/\/doi.org\/10.1245\/s10434-016-5097-3.","DOI":"10.1245\/s10434-016-5097-3"},{"key":"10.1016\/j.anndiagpath.2021.151755_bb0150","doi-asserted-by":"crossref","unstructured":"Xiaoping L, Xiaowei Z, Leizhen Z, et al. Expression and significance of CD44 and p-AKT in pancreatic head cancer. World J Surg Oncol 2015; 13:334. doi:https:\/\/doi.org\/10.1186\/s12957-015-0746-8.","DOI":"10.1186\/s12957-015-0746-8"},{"key":"10.1016\/j.anndiagpath.2021.151755_bb0155","doi-asserted-by":"crossref","unstructured":"Jason You, Hushan Yang, Yinzhi Lai, et al. ARID2, p110\u03b1, p53, and \u03b2-catenin protein expression in hepatocellular carcinoma and clinicopathologic implications. Hum Pathol 2015;46, 1068\u20131077.doi:https:\/\/doi.org\/10.1016\/j.humpath.2015.05.005.","DOI":"10.1016\/j.humpath.2015.05.005"},{"key":"10.1016\/j.anndiagpath.2021.151755_bb0160","doi-asserted-by":"crossref","unstructured":"Vantler M, Jesus J, Lepp\u00e4nen O, etal, Class IA phosphatidylinositol 3-kinase isoform p110\u03b1 mediates vascular remodeling. Arterioscler Thromb Vasc Biol 2015; Jun,35(6):1434\u201344. doi:https:\/\/doi.org\/10.1161\/atvbaha.114.304887.","DOI":"10.1161\/ATVBAHA.114.304887"},{"key":"10.1016\/j.anndiagpath.2021.151755_bb0165","doi-asserted-by":"crossref","unstructured":"Mariona Graupera, Julie Guillermet-Guibert, Lazaros C Foukas. Angiogenesis selectively requires the p110alpha isoform of PI3K to control endothelial cell migration. Nature 2008; May 29;453(7195):662\u20136. doi:https:\/\/doi.org\/10.1038\/nature06892.","DOI":"10.1038\/nature06892"},{"key":"10.1016\/j.anndiagpath.2021.151755_bb0170","doi-asserted-by":"crossref","unstructured":"Yile Zhou, Yajie Yang, Tao Liang. et al. The regulatory effect of microRNA-21a-3p on the promotion of telocyte angiogenesis mediated by PI3K (p110\u03b1)\/AKT\/mTOR in LPS induced mice ARDS. J Transl Med 2019; Dec 26;17(1):427. doi:https:\/\/doi.org\/10.1186\/s12967-019-02168-z.","DOI":"10.1186\/s12967-019-02168-z"},{"key":"10.1016\/j.anndiagpath.2021.151755_bb0175","doi-asserted-by":"crossref","unstructured":"Singh P, Dar MS, Dar MJ. p110\u03b1 and p110\u03b2 isoforms of PI3K signaling: are they two sides of the same coin? FEBS Lett 2016; Sep;590(18):3071\u201382.doi:https:\/\/doi.org\/10.1002\/1873-3468.12377.","DOI":"10.1002\/1873-3468.12377"},{"key":"10.1016\/j.anndiagpath.2021.151755_bb0180","doi-asserted-by":"crossref","unstructured":"Fatemeh Mazloumi Gavgani, Victoria Smith Arnesen, Rh\u00eean G Jacobsen. Class I phosphoinositide 3-kinase PIK3CA\/p110\u03b1 and PIK3CB\/p110\u03b2 isoforms in endometrial cancer. Int J Mol Sci 2018; Dec 7;19(12):3931. doi:https:\/\/doi.org\/10.3390\/ijms19123931.","DOI":"10.3390\/ijms19123931"},{"key":"10.1016\/j.anndiagpath.2021.151755_bb0185","doi-asserted-by":"crossref","unstructured":"Denley A, Kang S, Karst U, et al. Oncogenic signaling of class I PI3K isoforms. Oncogene 2008;27(18):2561\u20132574.doi:https:\/\/doi.org\/10.1038\/sj.onc.1210918.","DOI":"10.1038\/sj.onc.1210918"},{"key":"10.1016\/j.anndiagpath.2021.151755_bb0190","doi-asserted-by":"crossref","unstructured":"Bilancio Antonio, Rinaldi Barbara, Oliviero Maria Antonietta, et al. Inhibition of p110\u03b4 PI3K prevents inflammatory response and restenosis after artery injury. Biosci Rep 2017; Sep 27;37(5). doi:https:\/\/doi.org\/10.1042\/bsr20171112.","DOI":"10.1042\/BSR20171112"},{"key":"10.1016\/j.anndiagpath.2021.151755_bb0195","unstructured":"Chuanlei Yang, Xing Chen, Zhanjie Wei,et al. Targeting the class IA PI3K isoforms p110\u03b1\/\u03b4 attenuates heart allograft rejection in mice by suppressing the CD4+T lymphocyte response. Am J Transl Res 2018;May 15;10(5):1387\u20131399 http:\/\/www.ncbi.nlm.nih.gov\/pmc\/articles\/pmc5992545\/."},{"key":"10.1016\/j.anndiagpath.2021.151755_bb0200","doi-asserted-by":"crossref","unstructured":"Ali K, Soond DR, Pineiro R, Hagemann T, Pearce W, Lim EL, et al. Inactivation of PI3K p110delta breaks regulatory T-cell-mediated immune tolerance to cancer. Nature 2014; 510:407\u2013411. doi:https:\/\/doi.org\/10.1038\/nature13444.","DOI":"10.1038\/nature13444"},{"key":"10.1016\/j.anndiagpath.2021.151755_bb0205","doi-asserted-by":"crossref","unstructured":"Qingshan Yang, Prexy Modi, Terry Newcomb, et al. Idelalisib: first-in-class PI3K delta inhibitor for the treatment of chronic lymphocytic leukemia, small lymphocytic leukemia, and follicular lymphoma. Clin Cancer Res 2015; April 1; 21(7): 1537\u20131542. doi:https:\/\/doi.org\/10.1158\/1078-0432.ccr-14-2034.","DOI":"10.1158\/1078-0432.CCR-14-2034"},{"key":"10.1016\/j.anndiagpath.2021.151755_bb0210","doi-asserted-by":"crossref","unstructured":"Wenyi Wu, Guohong Zhou, Haote Han. PI3K\u03b4 as a novel therapeutic target in pathological angiogenesis. Diabetes 2020; Apr; 69(4):736\u2013748. doi:https:\/\/doi.org\/10.2337\/db19-0713.","DOI":"10.2337\/db19-0713"},{"key":"10.1016\/j.anndiagpath.2021.151755_bb0215","doi-asserted-by":"crossref","unstructured":"Braden D Siempelkamp, Manoj K Rathinaswamy, Meredith L Jenkins. Molecular mechanism of activation of class IA phosphoinositide 3-kinases (PI3Ks) by membrane-localized HRas. J Biol Chem 2017; Jul 21;292(29):12256\u201312266. doi:https:\/\/doi.org\/10.1074\/jbc.m117.789263.","DOI":"10.1074\/jbc.M117.789263"}],"container-title":["Annals of Diagnostic Pathology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1092913421000551?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1092913421000551?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,21]],"date-time":"2025-10-21T20:32:48Z","timestamp":1761078768000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1092913421000551"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,8]]},"references-count":43,"alternative-id":["S1092913421000551"],"URL":"https:\/\/doi.org\/10.1016\/j.anndiagpath.2021.151755","relation":{},"ISSN":["1092-9134"],"issn-type":[{"value":"1092-9134","type":"print"}],"subject":[],"published":{"date-parts":[[2021,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"The role of different PI3K protein subtypes in the metastasis, angiogenesis and clinical prognosis of hepatocellular carcinoma","name":"articletitle","label":"Article Title"},{"value":"Annals of Diagnostic Pathology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.anndiagpath.2021.151755","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 The Authors. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}],"article-number":"151755"}}